Small Ubiquitin-like Modifiers （SUMOs） are a family of small， related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation. Unlike ubiquitination， which targets proteins for degradation， sumoylation participates in a number of cellular processes， such as nuclear transport， transcriptional regulation， apoptosis， and protein stability. All SUMO proteins share the conserved ubiquitin domain and the C-terminal diglycine cleavage/attachment site. Human SUMO2， also known as Sentrin2 and SMT3B is synthesized as a 95 amino acid （aa）， 11 kDa propeptide that contains a two aa C-terminal prosegment， and an 18 aa N-terminal protein interacting region （aa 33 -50）. Following prosegment cleavage， the C-terminal glycine is enzymatically attached to a lysine on a target protein. Human SUMO2 shares 100% sequence identity to SUMO-2 from mouse. SUMO2 also has very high sequence homology to SUMO3 and SUMO4， 86 % and 85%， respectivel
应用类型
ELISA， Western blot and Immunofluorescence
免疫原
Anti-human SUMO2/3 mAb， is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human SUMO2 amino acids 1-93 purified from E. coli.
